Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral t cell lymphoma (PTCL).

e19532Background: Pre-clinical data suggest a role for SYK and JAK signaling pathways as oncogenic drivers in PTCL. Most compelling is the frequent demonstration of SYK expression (not expressed in...